What the company does
Union Korea Pharm makes prescription medicines, including antibiotics, musculoskeletal, cardiovascular, and digestive drugs, supplied to hospitals and pharmacies in South Korea and exported to markets across the Middle East, Southeast Asia, and Latin America.
Listed on KOSDAQ, South Korea's small-cap board, the company serves both domestic healthcare providers and overseas buyers. Its business runs across three streams: domestic prescription-drug sales, international exports of finished medicines, and contract manufacturing (CMO), producing finished drugs on behalf of other pharmaceutical companies that lack certain production facilities.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$45.8M
- FY2024US$37.2M
- FY2025US$26.4M
Operating profit
- FY2023−US$3.8M
- FY2024−US$9.7M
- FY2025−US$12.5M
Net income
- FY2023−US$13.2M
- FY2024−US$15.1M
- FY2025−US$22.3M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company also outsources production of dosage forms it does not manufacture in-house to third-party firms, a mutual arrangement it describes as strategically complementing its own product lineup.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?